- Home
- CHI vs AVTX Comparison
CHI vs AVTX Comparison
Compare CHI & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHI | AVTX |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 982.5M |
| IPO Year | 2002 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CHI | AVTX |
|---|---|---|
| Price | $12.98 | $19.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $40.57 |
| AVG Volume (30 Days) | 147.6K | ★ 729.8K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $10.26 | $8.65 |
| 52 Week High | $13.50 | $24.27 |
Technical Indicators
Market Signals| Indicator | CHI | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.20 | 55.53 |
| Support Level | $12.95 | $17.40 |
| Resistance Level | $13.49 | $20.68 |
| Average True Range (ATR) | 0.18 | 1.06 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 27.54 | 66.12 |
Price Performance
Historical ComparisonAbout CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.